<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335604</url>
  </required_header>
  <id_info>
    <org_study_id>NOV140201-101</org_study_id>
    <nct_id>NCT04335604</nct_id>
  </id_info>
  <brief_title>A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Dose-finding, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile of NOV140201 (JPI-547), a Dual Inhibitor of PARP/TNK in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National OncoVenture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National OncoVenture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy&#xD;
      of JPI-547 in patients with advanced solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1 dose escalation and expansion study of NOV140201 (JPI-547) to&#xD;
      evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor&#xD;
      efficacy of JPI-547 in patients with advanced solid tumors after failure of standard of care.&#xD;
&#xD;
      Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase. DLTs&#xD;
      will be assessed as the primary endpoint in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) and Maximum tolerated dose (MTD)</measure>
    <time_frame>21days</time_frame>
    <description>subjects will be treated and observed for DLT through the end of the first cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of JPI-547</measure>
    <time_frame>1 and 15 days</time_frame>
    <description>to observe pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of JPI-547</measure>
    <time_frame>1 and 15 days</time_frame>
    <description>to observe pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at maximum concentration(Tmax) of JPI-547</measure>
    <time_frame>1 and 15 days</time_frame>
    <description>to observe pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of JPI-547</measure>
    <time_frame>1 and 15 days</time_frame>
    <description>to observe pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of JPI-547</measure>
    <time_frame>1 and 15 days</time_frame>
    <description>to observe pharmacokinetic parameter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>JPI-547</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JPI-547</intervention_name>
    <description>The dose levels will be escalated following a 3+3 dose escalation scheme.</description>
    <arm_group_label>JPI-547</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged 19 years old or above&#xD;
&#xD;
          -  Patients that are histologically or cytologically confirmed advanced solid tumors and&#xD;
             are refractory to or are able to receive standard of care&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥12 weeks&#xD;
&#xD;
          -  Individuals who volunteer to give to the written consent to the participation after&#xD;
             listening to sufficient explanation for this clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe drug hypersensitivity or hypersensitivity to IP or similar class&#xD;
&#xD;
          -  Patients who have the confirmed medical history or surgery/procedure history as the&#xD;
             followings:&#xD;
&#xD;
               1. History of major surgery requiring general anesthesia or assisted respiration&#xD;
                  within 4 weeks prior to baseline (within 2 weeks for video-assisted thoracoscopic&#xD;
                  surgery (VATS) or open-and-closed (ONC) surgery)&#xD;
&#xD;
               2. Severe cardiovascular disease (eg. myocardial infarction or unstable angina&#xD;
                  pectoris) within 24 weeks prior to baseline&#xD;
&#xD;
               3. New York Heart Association Class III or IV heart failure within 24 weeks prior to&#xD;
                  baseline&#xD;
&#xD;
               4. Severe cerebrovascular disease within 24 weeks prior to baseline&#xD;
&#xD;
               5. Pulmonary artery thrombosis, deep vein thrombosis, or clinically severe pulmonary&#xD;
                  disease within 24 weeks prior to baseline&#xD;
&#xD;
               6. Infection requiring the administration of systemic antibiotics, antivirals or&#xD;
                  other uncontrolled Grade ≥3 Active infectious disease within 2 weeks prior to&#xD;
                  baseline&#xD;
&#xD;
               7. Symptomatic interstitial lung disease&#xD;
&#xD;
               8. Poor recovery from hematologic toxicities in previous anticancer treatment (eg.&#xD;
                  &gt;4 weeks of Grade 3≥ toxicities)&#xD;
&#xD;
               9. Individuals who receive bone marrow or stem cell transplant with a high dose of&#xD;
                  chemotherapy&#xD;
&#xD;
          -  Individuals as accompanied by the following diseases:&#xD;
&#xD;
               1. Hematologic malignancy other than lymphoma&#xD;
&#xD;
               2. History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test&#xD;
                  results indicative of the risk of MDS/acute myelocytic leukemia (AML)&#xD;
&#xD;
               3. Patients with symptomatic with clinically significant or uncontrolled central&#xD;
                  nervous system (CNS) or brain metastasis (other than patients who discontinued&#xD;
                  the administration of systematic corticosteroid at least 4 weeks prior to&#xD;
                  baseline and who are radiologically and neurologically stable for ≥4 weeks)&#xD;
&#xD;
               4. Patients with clinically significant abnormalities in the judgment of the&#xD;
                  investigator according to electrocardiogram findings&#xD;
&#xD;
               5. Uncontrolled hypertension (systolic blood pressure&gt;140mmHg or diastolic blood&#xD;
                  pressure &gt;90mmHg)&#xD;
&#xD;
               6. Bleeding diatheses&#xD;
&#xD;
               7. History of active hepatitis B or C virus (hepatitis patients acceptable if HBV&#xD;
                  DNA and HCV RNA are &lt;institutional lower limits)&#xD;
&#xD;
               8. positive known human immunodeficiency virus (HIV)infection&#xD;
&#xD;
               9. Severe neurological disorder and mental illness that may affect the study results&#xD;
                  in the opinion of the investigator&#xD;
&#xD;
          -  Individuals who have the following medication history:&#xD;
&#xD;
               1. Individuals with medication history of PARP inhibitors or TNK inhibitors (This&#xD;
                  applies only to Part 2.)&#xD;
&#xD;
               2. Individuals receiving chemotherapy, biological therapy, retinoid therapy,&#xD;
                  immunotherapy, hormone therapy or therapeutic/palliative radiotherapy for the&#xD;
                  treatment of advanced solid tumors within 4 weeks prior to baseline (except for&#xD;
                  the individuals who received nitrosourea or mitomycin within 6 weeks prior to&#xD;
                  baseline and biological target antibody within 6 weeks prior to baseline)&#xD;
&#xD;
               3. Patients requiring the continuous administration of non-steroidal&#xD;
                  anti-inflammatory drug (NSAID) with a high bleeding risk&#xD;
&#xD;
               4. Patients requiring continuous administration of systemic corticosteroid&#xD;
                  equivalent to Prednisone &gt;10 mg/day&#xD;
&#xD;
               5. Individuals who received antithrombotics, including antiplatelets and&#xD;
                  anticoagulants within 2 weeks of baseline, or expecting to require the&#xD;
                  administration during the clinical study (the administration of low molecular&#xD;
                  weight heparin (LMWH) is allowed for the management and prevention of venous&#xD;
                  thrombosis during the clinical study.)&#xD;
&#xD;
               6. Individuals who start the new administration or dose change of bisphosphonate&#xD;
                  within 30 days of baseline among patients with breast cancer and prostatic cancer&#xD;
                  in a dose expansion cohort within 30 days of baseline (bisphosphonate&#xD;
                  administered stably for 30 days before baseline is allowed.)&#xD;
&#xD;
          -  Pregnant women, breastfeeding women, or female of childbearing potential and male who&#xD;
             are not willing to practice abstinence or use appropriate contraception* during the&#xD;
             clinical study and for 3 months after the administration of the IP&#xD;
&#xD;
          -  Individuals who were administered other IPs or the investigational device within 4&#xD;
             weeks prior to baseline&#xD;
&#xD;
          -  Individual considered ineligible or unavailable for this study for other reasons, in&#xD;
             the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hoon-Kyo Kim, MD</last_name>
    <phone>+82-31-920-2784</phone>
    <email>miongsok@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nam-Seok Baek</last_name>
    <phone>+82-31-920-2782</phone>
    <email>i20371@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jee Hyun Kim, M.D., Ph.D.</last_name>
      <email>jhkimmd@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Jue Bang, MD</last_name>
      <email>bangyj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

